Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2024)

Immix Biopharma has disclosed Total Non-Current Liabilities across 5 years of filings, most recently posting $9.7 million for Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $9.7 million, up 160.54% year-over-year; the trailing twelve-month figure through Dec 2024 was $9.7 million (up 160.54% YoY), and the FY2024 annual result was $9.7 million, up 160.54% from the prior year.
• Total Non-Current Liabilities came in at $9.7 million for Q4 2024 at Immix Biopharma, up from $7.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $9.7 million in Q4 2024 to a low of -$23.2 million in Q4 2021.
• The 5-year median for Total Non-Current Liabilities is $4.8 million (2020), against an average of $2.0 million.
• Across the five-year window, Total Non-Current Liabilities slumped 594.4% in 2021 and surged 160.54% in 2024, its largest moves.
• Immix Biopharma's Total Non-Current Liabilities stood at $4.7 million in 2020, then plunged by 594.4% to -$23.2 million in 2021, then soared by 107.53% to $1.7 million in 2022, then jumped by 112.88% to $3.7 million in 2023, then soared by 160.54% to $9.7 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $9.7 million (Q4 2024), $7.6 million (Q3 2024), and $4.9 million (Q2 2024), per Business Quant data.